Seeking Alpha upgrade lacks new evidence; maintain WAIT on TEM

What happened

A Seeking Alpha article now calls Tempus AI a higher-conviction Buy, citing resolved MRD ownership via the Personalis acquisition, positive adjusted EBITDA, xT CDx FDA approval, and ~28% Data and Applications growth. These are not new developments: our master report already incorporated the Personalis deal (announced July 20, 2026), Q2 2026 adjusted EBITDA of $8.0 million, FDA approval for xT CDx, and Data and Applications growth of 28%. The article overlooks that Personalis has not closed, GAAP net losses persist (1H26 loss of $120.3 million), and management guidance excludes Personalis impact. The stock's 31% drop over the past year does not automatically create margin of safety given a $7.3 billion market cap, price-to-book near 18, and negative EPS. We see no new evidence that the integration will preserve the path to ~$65 million adjusted EBITDA or that dilution risk has been eliminated.

Implication

If Data and Applications growth stays above 28% and Personalis integration proves financially neutral with unchanged EBITDA guidance, the stock could re-rate toward our $58 bull case. Until then, the current price near $44 offers no margin of safety; consider building a position only on pullbacks toward our $38 attractive entry.

Thesis delta

The news article does not materially shift our thesis; it restates known positives without resolving the core uncertainty around Personalis integration and GAAP profitability. Our WAIT rating remains because the upgrade trigger—Data and Applications growth above 28% together with Personalis included in unchanged EBITDA guidance—has not yet occurred. The article's bullishness appears premature without new filings or deal closure.